Core Insights - Edesa Biotech's CEO, Dr. Par Nijhawan, has been selected to present at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the Phase 3 results for paridiprubart in treating ARDS patients [1][3] Group 1: Presentation and Study Results - Dr. Nijhawan's presentation will focus on findings from the Phase 3 study of paridiprubart (EB05), an anti-TLR4 antibody for Acute Respiratory Distress Syndrome (ARDS), which leads to over three million ICU admissions globally each year [2] - The Phase 3 results include data from an initial 104 patients requiring invasive mechanical ventilation and expanded results from a broader 278-patient population, reinforcing the potential clinical benefits of paridiprubart [2] Group 2: Upcoming Events - The presentation by Dr. Nijhawan is scheduled for May 15, 2026, with an accompanying poster presentation by Edesa's research team at the summit [3] - Ted Steiner, MD, will present a full oral presentation of the Phase 3 results on May 20, 2026, during the ATS 2026 International Conference, focusing on the study's design and outcomes [4] Group 3: Product Overview - Paridiprubart is a new class of host-directed therapeutics designed to modulate the immune response against various health threats, including infectious diseases and other public health emergencies [5] - The drug works by inhibiting toll-like receptor 4 (TLR4), which is activated by various pathogens and is involved in chronic autoimmune diseases [5] Group 4: Company Background - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory and immune-related diseases, with a pipeline that includes therapies for both medical dermatology and respiratory conditions [6] - The company is developing EB06 for vitiligo and EB01 for allergic contact dermatitis, alongside its lead respiratory candidate, paridiprubart, which is supported by funding from the Government of Canada [6]

Core Insights - Edesa Biotech, Inc. has announced that its CEO, Dr. Par Nijhawan, will deliver the inaugural presentation at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the company's Phase 3 study results for paridiprubart, an anti-TLR4 antibody for treating Acute Respiratory Distress Syndrome (ARDS) [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, with a clinical pipeline targeting Medical Dermatology and Respiratory conditions [6] - The company is developing paridiprubart (EB05) as a treatment for ARDS, a condition that leads to over three million ICU admissions globally each year [2][6] Clinical Study Details - The Phase 3 study of paridiprubart has reported results from an initial cohort of 104 patients requiring invasive mechanical ventilation, followed by expanded results from a total of 278 patients, indicating potential clinical benefits [2] - Dr. Ted Steiner, the principal investigator of the Phase 3 study, will present comprehensive results at the ATS 2026 International Conference on May 20, 2026 [4] Presentation Significance - Dr. Nijhawan expressed that being invited to lead the innovation showcase is a validation of the strength of the Phase 3 data and the potential of paridiprubart to transform ARDS treatment, which currently has limited effective options [3] Therapeutic Mechanism - Paridiprubart represents a new class of host-directed therapeutics designed to modulate the immune response against various public health threats, including infectious diseases and other emergencies [5]

Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases [1][3] - The company has a clinical pipeline targeting two therapeutic areas: Medical Dermatology and Respiratory [3] Medical Dermatology - Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate for treating vitiligo, an autoimmune disorder [3] - The company also has EB01 (1.0% daniluromer cream), which is Phase 3-ready for moderate-to-severe chronic Allergic Contact Dermatitis (ACD) [3] Respiratory - The most advanced respiratory drug candidate is EB05 (paridiprubart), currently evaluated in a U.S. government-funded study for Acute Respiratory Distress Syndrome [3] - EB05 has received two funding awards from the Government of Canada to support its development [3] - Edesa is preparing an investigational new drug application (IND) for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis [3] Upcoming Events - Edesa will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference on May 5-6, 2025, in Toronto [1][2] - Management is scheduled to present on May 5 at 4:00pm ET [2]